LONDON (Alliance News) - PureTech Health PLC said Monday that affiliate Karuna Pharmaceuticals Inc started a Phase 2 study of KarXT, its lead product in the treatment of psychosis in schizophrenia.
The Phase 2 study of KArXT, karuna-xanomeline-trospium, aims to reproduce the significant efficacy previously observed in a schizophrenia trial with xanomeline alone.
The company expects top-line data results at the end of 2019.
PureTech Chief of Research & Strategy Eric Elenko said: "We are pleased with the progress Karuna has made to advance KarXT into a Phase 2 study, bringing us one step closer to potentially delivering the first new mechanism in more than 60 years for the treatment of psychosis in schizophrenia.
"We have now demonstrated the tolerability of KarXT in two Phase 1 studies, including most recently with a proprietary formulation of KarXT, and we look forward to the results from the Phase 2 study."
PureTech's shares were trading up 3.4% at 166.50 pence each.
PureTech (PRTC)